|
CSRNP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.86530000001461E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.65817999999707E-05 |
| Normal-vs-Stage2 |
1.67529999994809E-06 |
| Normal-vs-Stage3 |
4.85529999982859E-07 |
| Normal-vs-Stage4 |
1.26430000002564E-06 |
| Stage1-vs-Stage2 |
2.566600E-01 |
| Stage1-vs-Stage3 |
6.933600E-02 |
| Stage1-vs-Stage4 |
2.008800E-01 |
| Stage2-vs-Stage3 |
7.537800E-01 |
| Stage2-vs-Stage4 |
9.148600E-01 |
| Stage3-vs-Stage4 |
8.420600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.06350000003997E-06 |
| Normal-vs-AfricanAmerican |
2.966300E-04 |
| Normal-vs-Asian |
3.53600000002618E-06 |
| Caucasian-vs-AfricanAmerican |
5.907200E-01 |
| Caucasian-vs-Asian |
5.192200E-01 |
| AfricanAmerican-vs-Asian |
3.176400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62710000028987E-07 |
| Normal-vs-Female |
1.53426999999207E-05 |
| Male-vs-Female |
4.864600E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.55410000000278E-05 |
| Normal-vs-Age(41-60Yrs) |
1.38289999995767E-06 |
| Normal-vs-Age(61-80Yrs) |
1.17899999985127E-07 |
| Normal-vs-Age(81-100Yrs) |
1.636950E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.433600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.695980E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.151400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.045020E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.468800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.134600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.138720E-03 |
| Classical-VS-Follicular |
6.321800E-01 |
| Classical-VS-Other |
8.085500E-02 |
| Classical-VS-Normal |
1.5257999999907E-05 |
| Tall-VS-Follicular |
4.114300E-02 |
| Tall-VS-Other |
7.357600E-01 |
| Tall-VS-Normal |
3.84589999846696E-08 |
| Follicular-VS-Other |
2.127800E-01 |
| Follicular-VS-Normal |
1.59771999999059E-05 |
| Other-VS-Normal |
1.18709999996636E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.11259999949709E-07 |
| Normal-vs-N1 |
1.18429999995673E-06 |
| N0-vs-N1 |
9.517000E-01 |
|
|
